key: cord-0834367-r1qs3x0x
authors: Mieczkowska, Karolina; Deutsch, Alana; Borok, Jenna; Guzman, Anthony K.; Fruchter, Renee; Patel, Parth; Wind, Olivia; McLellan, Beth N.; Mann, Ranon E.; Halverstam, Caroline P.
title: Telogen effluvium: a sequela of COVID‐19
date: 2020-11-23
journal: Int J Dermatol
DOI: 10.1111/ijd.15313
sha: 089cf1f1f2bf40a83e426629f928476c352696fd
doc_id: 834367
cord_uid: r1qs3x0x

nan

However, cutaneous signs and symptoms of disease have also been described and may significantly impact patients. 2 While preliminary characterizations have aptly set expectations for acute disease course, it is imperative to establish similar familiarity with late-course and postinfectious manifestations to guide appropriate treatment and patient education. Our patient population located in New York City, which was an early epicenter of disease, demonstrates elements of virus-induced late sequelae.

In the ambulatory dermatology clinic, one such increasingly apparent manifestation has been new onset diffuse hair loss in patients previously infected with SARS-CoV-2, clinically compatible with telogen effluvium (TE). TE is characterized by diffuse hair loss within months of a significant systemic stressor because of premature follicular transition from the anagen (active growth phase) to the telogen (resting phase). The telogen phase lasts approximately 3 months, after which excessive hair loss ensues. 3 Herein, we present 10 patients with concerns of increased hair loss following SARS-CoV-2 infection ( Proper reassurance and education, however, is essential 3 and highlights the vital role that telemedicine has played over the past months in maintaining high-level dermatologic care for our vulnerable population. 5 While intuitive that this phenomenon of TE secondary to COVID-19 exists, as it has been similarly reported in recent scientific literature and lay media, it nonetheless remains imperative to increase awareness as to its possibility. With increasing numbers of recovering patients, the risk of developing this physically and emotionally distressing dermatologic manifestation will likely continue. 5, 6 Availability of data

The data supporting the findings discussed are available within the article. 

COVID-19 pandemic: cardiovascular complications and future implications

A review of the dermatological manifestations of coronavirus disease

Telogen effluvium: a review of the literature

Female pattern hair loss: a clinical, pathophysiologic, and therapeutic review

Management of telogen effluvium during the COVID-19 emergency: psychological implications

Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire